Childhood obesity stories

Sep 7, 2026

Novo Nordisk's Wegovy helps 40% of young children lose enough weight to no longer be obese in trial

In a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide (Wegovy's active ingredient) were no longer obese after treatment, compared to the control group.

Sep 7, 20262 sources

Jul 25, 2026

Italy faces severe childhood obesity crisis despite Mediterranean diet heritage

Italy, once a model for healthy eating with its Mediterranean diet, now confronts a major child obesity problem, with over 40% of children aged 8-9 overweight in some regions of Campania. The crisis represents a stark reversal for a country that inspired global healthy eating standards.

Jul 25, 20267 sources

Top claims

▪A majority of the children enrolled in Novo Nordisk's STEP Young trial had a body mass index that placed them in a high obesity range at the start of the study
▪GLP-1 weight-loss drugs are not approved for children under the age of 12 in the United States, despite a significant rise in prescriptions for this age group
▪In Novo Nordisk's late-stage STEP Young trial, 40.4% of children aged 6 to under 12 treated with semaglutide were no longer classified as obese after 68 weeks, assuming full adherence

Subtopics

Clinical trials1 Dietary patterns1 GLP-1 medications1 Lifestyle, Wellness and Nutrition1 Mediterranean diet1 Novo Nordisk1 Nutrition1 Pharma1 Weight management1

Related timelines